Hematology, transfusion and cell therapy · 2026
Immature platelets: A useful tool for thrombocytopenia etiology classification in adults.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pimentel Raphael Ferreira, Leal Dos Santos Tayná Regina, Bezerra Marcos André Cavalcanti, Hatzlhofer Betânia Lucena Domingues, Muniz Maria Tereza Cartaxo
Аннотация
INTRODUCTION: The etiology of thrombocytopenia is diverse with heterogenous clinical manifestations which demand the correct diagnosis and appropriate management. The immature platelet fraction is associated with new platelet release from the bone marrow by thrombopoiesis. The clinical utility of this low-cost, feasible measurement has been demonstrated across various conditions. This study aimed to assess the immature platelet fraction and count as diagnostic tests to distinguish between the two main causes of thrombocytopenia in selected hematology disorders.
METHODS: A total of 444 participants were evaluated: Group 1 (n = 179; healthy blood donors), Group 2 (n = 131; peripheral platelet destruction or consumption, including immune thrombocytopenia and thrombotic thrombocytopenic purpura), and Group 3 (n = 134; bone marrow failure secondary to aplastic anemia, chemotherapy, acute leukemia, or multiple myeloma).
RESULTS: Median immature platelet fraction (%) and immature platelet count (× 109/L) values were 3.3/8.1 (Group 1), 16.5/6.1 (Group 2), and 5.0/1.8 (Group 3), with significant intergroup differences between Groups 2 and 3 (p-value <0.001). Optimal diagnostic cut-offs were 8.3% for immature platelet fraction (AUC = 0.8585) and 3.1 × 109/L for immature platelet count (AUC = 0.7687). The immature platelet fraction was highest in immune thrombocytopenia patients and showed significant inverse correlations with platelet counts in Groups 1 and 2 (p-value <0.001).
CONCLUSION: Immature platelet fraction and immature platelet count can be useful to discriminate between the main etiologies and should be included in the routine of hematology centers for screening thrombocytopenia.
METHODS: A total of 444 participants were evaluated: Group 1 (n = 179; healthy blood donors), Group 2 (n = 131; peripheral platelet destruction or consumption, including immune thrombocytopenia and thrombotic thrombocytopenic purpura), and Group 3 (n = 134; bone marrow failure secondary to aplastic anemia, chemotherapy, acute leukemia, or multiple myeloma).
RESULTS: Median immature platelet fraction (%) and immature platelet count (× 109/L) values were 3.3/8.1 (Group 1), 16.5/6.1 (Group 2), and 5.0/1.8 (Group 3), with significant intergroup differences between Groups 2 and 3 (p-value <0.001). Optimal diagnostic cut-offs were 8.3% for immature platelet fraction (AUC = 0.8585) and 3.1 × 109/L for immature platelet count (AUC = 0.7687). The immature platelet fraction was highest in immune thrombocytopenia patients and showed significant inverse correlations with platelet counts in Groups 1 and 2 (p-value <0.001).
CONCLUSION: Immature platelet fraction and immature platelet count can be useful to discriminate between the main etiologies and should be included in the routine of hematology centers for screening thrombocytopenia.